Autres langues Satellos Bioscience Inc.

Actions

MSCL

CA80401L8033

Recherche biotechnologique et médicale

Marché Fermé - Toronto S.E. Autres places de cotation 21:59:56 11/08/2026			Varia. 5j.	Varia. 1 janv.
14,11 ^CAD	+1,88%		-0,35%	+78,16%

08/07	Satellos Bioscience Inc. publie les données intermédiaires à six mois de l'étude TRAILHEAD sur le SAT-3247 chez des adultes atteints de la dystrophie musculaire de Duchenne	CI
08/07	Satellos : les données intérimaires de phase 2 montrent que le SAT-3247 améliore les mesures musculaires chez les adultes atteints de DMD	MT

Autres langues

08/07	Satellos Bioscience Inc. Reports Six-Month Interim Trailhead Data for Sat-3247 in Adults with Duchenne Muscular Dystrophy
08/07	Satellos Says Interim Phase 2 Data Shows SAT-3247 Improves Muscle Measures in Adult DMD Patients
08/07	Satellos Reports Six-Month Interim TRAILHEAD Data Showing Reduced Muscle Fat Fraction, Increased Effort, Stable Strength, Lower CK and Favorable Safety Profile in DMD Adults Treated with SAT-3247
29/06	Satellos Bioscience up near 10% as SAT-3247 Granted FDA Fast Track Designation
29/06	Satellos Bioscience Shares Climb After FDA Fast Track Designation
29/06	Satellos Bioscience' SAT-3247 Secures US FDA Fast Track Status in Duchenne Muscular Dystrophy
29/06	Satellos Bioscience Inc. Receives FDA Fast Track Designation For SAT-3247 For The Treatment Of Duchenne Muscular Dystrophy
29/06	Satellos Receives FDA Fast Track Designation for SAT-3247 for the Treatment of Duchenne Muscular Dystrophy
25/06	Satellos Bioscience to Present New Data at International Congress Next Month
25/06	Satellos to Present Clinical Program Updates at ICNMD 2026
17/06	Satellos Bioscience Announces Results of Annual Meeting of Shareholders
27/05	Satellos to Participate in Upcoming Investor Conferences
15/05	Satellos Bioscience : First Quarter 2026 Financial Results and Operational Highlights
15/05	Satellos Bioscience : First Quarter 2026 Management’s Discussion Analysis
15/05	Satellos Bioscience: Q1 Earnings Snapshot
15/05	Satellos Reports First Quarter 2026 Financial Results and Highlights Company Progress
15/05	Satellos Bioscience Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
07/05	15,424,440 Common Shares of Satellos Bioscience Inc. are subject to a Lock-Up Agreement Ending on 7-MAY-2026.
07/05	Certain Stock Options of Satellos Bioscience Inc. are subject to a Lock-Up Agreement Ending on 7-MAY-2026.
07/05	Certain Pre-Funded Warrants of Satellos Bioscience Inc. are subject to a Lock-Up Agreement Ending on 7-MAY-2026.
05/05	Investor Presentation 04/22/2026 00:00:00
23/04	Satellos Bioscience : 2026 Bloom Burton & Co. Healthcare Investor Conference Presentation
09/04	Satellos to Present at the Bloom Burton & Co. Healthcare Investor Conference
30/03	Satellos Reports 2025 Financial Results and Highlights Recent Company Progress
27/03	Satellos Bioscience Inc. Reports Earnings Results for the Full Year Ended December 31, 2025